Expression of prostate apoptosis response (Par-4) is associated with progesterone receptor in breast cancer.

[1]  W. Fan,et al.  The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study , 2009, BMC Cancer.

[2]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[3]  Zhiwei Wang,et al.  Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis , 2008, Molecular Cancer Therapeutics.

[4]  H. Hsu,et al.  Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines. , 2007, Cancer letters.

[5]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[7]  M. Serrano,et al.  Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. , 2007, Cancer research.

[8]  Zhengxin Wang,et al.  Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. , 2006, Journal of molecular endocrinology.

[9]  M. Schumacher,et al.  Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients , 2006, Clinical Cancer Research.

[10]  V. Rangnekar,et al.  Regulation of Cancer Cell Survival by Par‐4 , 2005, Annals of the New York Academy of Sciences.

[11]  D. Rimm,et al.  Immunohistochemical Biomarkers in Patients with Early‐Onset Breast Carcinoma by Tissue Microarray , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Der,et al.  Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells* , 2005, Journal of Biological Chemistry.

[13]  M. Serrano,et al.  Tumour‐suppression activity of the proapoptotic regulator Par4 , 2005, EMBO reports.

[14]  Y. Ogawa,et al.  Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. , 2005, Radiation medicine.

[15]  V. Rangnekar,et al.  Par‐4 inducible apoptosis in prostate cancer cells , 2004, Journal of cellular biochemistry.

[16]  Sandip K. Mishra,et al.  Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter* , 2003, Journal of Biological Chemistry.

[17]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Rowinsky,et al.  The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.

[19]  Mansoor M Ahmed,et al.  Par-4, A Pro-Apoptotic Gene, Inhibits Radiation-Induced NFκB Activity and Bcl-2 Expression Leading to Induction of Radiosensitivity in Human Prostate Cancer Cells PC-3 , 2002, Cancer biology & therapy.

[20]  V. Rangnekar,et al.  Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. , 2001, Cancer research.

[21]  M. Duffy,et al.  Biochemical markers in breast cancer: which ones are clinically useful? , 2001, Clinical biochemistry.

[22]  M. Brizzi,et al.  p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  M. Serrano,et al.  The downregulation of the pro‐apoptotic protein Par‐4 is critical for Ras‐induced survival and tumor progression , 1999, The EMBO journal.

[24]  M. Mattson,et al.  Prostate Apoptosis Response‐4 Mediates Trophic Factor Withdrawal‐Induced Apoptosis of Hippocampal Neurons , 1999, Journal of neurochemistry.

[25]  W. Linehan,et al.  Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma , 1999, Oncogene.

[26]  V. Rangnekar,et al.  Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4 , 1999, Oncogene.

[27]  B. Asselain,et al.  Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome , 1998, Breast Cancer Research and Treatment.

[28]  M. Mattson,et al.  Expression and function of the leucine zipper protein Par-4 in apoptosis , 1997, Molecular and cellular biology.

[29]  H. Muss,et al.  Hormonal therapy of breast cancer: state of the art. , 1997, Oncology.

[30]  S. Humphreys,et al.  Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.